ENTRY       D09574                      Drug
NAME        Aflibercept (USAN/INN);
            Aflibercept (genetical recombination) (JAN);
            Ziv-aflibercept;
            Eylea (TN);
            Zaltrap (TN)
PRODUCT     EYLEA (Regeneron Pharmaceuticals)
            EYLEA HD (Regeneron Pharmaceuticals)
            ZALTRAP (sanofi-aventis U.S. LLC)
FORMULA     C4318H6788N1164O1304S32
EXACT_MASS  96837.1694
MOL_WEIGHT  96897.1957
SEQUENCE    SDTGRPFVEM YSEIPEIIHM TEGRELVIPC RVTSPNITVT LKKFPLDTLI PDGKRIIWDS
            RKGFIISNAT YKEIGLLTCE ATVNGHLYKT NYLTHRQTNT IIDVVLSPSH GIELSVGEKL
            VLNCTARTEL NVGIDFNWEY PSSKHQHKKL VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ
            GLYTCAASSG LMTKKNSTFV RVHEKDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR
            TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
            GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS
            DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH
            YTQKSLSLSP G
            (Disulfide bridge: 30-79, 124-185, 246-306, 352-410, 211-211', 214-214')
  TYPE      Peptide
REMARK      Therapeutic category: 1319
            ATC code: L01XX44 S01LA05
            Product: D09574<JP/US>
EFFICACY    Angiogenesis inhibitor
  DISEASE   Age-related macular degeneration [DS:H00821]
            Macular edema [DS:H01651]
            Diabetic macular edema [DS:H01651]
            Diabetic retinopathy [DS:H01457]
            Colorectal cancer [DS:H00020]
COMMENT     fusion protein
            VEGF-Trap
            Inhibitor of aberrant angiogenesis-vascular leak and inflammation, angiogenesis inhibitor for treatment of cancer
TARGET      VEGFA [HSA:7422] [KO:K05448]
            VEGFB [HSA:7423] [KO:K16858]
            PGF [HSA:5228] [KO:K16859]
  PATHWAY   hsa04370(7422)  VEGF signaling pathway
            hsa05200(5228+7422+7423)  Pathways in cancer
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XX Other antineoplastic agents
                 L01XX44 Aflibercept
                  D09574  Aflibercept (USAN/INN) &lt;JP/US&gt;
             S SENSORY ORGANS
              S01 OPHTHALMOLOGICALS
               S01L OCULAR VASCULAR DISORDER AGENTS
                S01LA Antineovascularisation agents
                 S01LA05 Aflibercept
                  D09574  Aflibercept (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Antineoplastics, Other
               Ziv-aflibercept
                D09574  Aflibercept (USAN/INN)
             Ophthalmic Agents
              Ophthalmic Agents, Other
               Vascular Endothelial Growth Factor (VEGF) Inhibitor
                Aflibercept
                 D09574  Aflibercept (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              13  Agents affecting sensory organs
               131  Ophthalmic agents
                1319  Others
                 D09574  Aflibercept (USAN/INN); Aflibercept (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Growth factors (RTK-binding)
                PGF
                 D09574  Aflibercept (USAN/INN) &lt;JP/US&gt;
                VEGFA
                 D09574  Aflibercept (USAN/INN) &lt;JP/US&gt;
                VEGFB
                 D09574  Aflibercept (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09574
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09574
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09574
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09574
DBLINKS     CAS: 862111-32-8
            PubChem: 124490314
///
